No specific pharmacological information is provided

It inhibits the transmembrane calcium ion influx of myocardial and vascular smooth muscle without changing the blood calcium concentration. Its effect on vascular smooth muscle is better than that on myocardial, so its vascular selectivity is strong. It selectively dilates coronary vascular smooth muscle, with minimal effect on heart rhythm and cardiac contractility. It reduces peripheral vascular resistance, and its effect on patients with hypertension is greater than that on patients with normal blood pressure. When blood pressure is lowered, there will be a reflex increase in heart rate. It increases cardiac ejection fraction and cardiac output, while the left ventricular end-diastolic pressure does not change much. It can reduce myocardial oxygen consumption and total peripheral resistance, and can also increase coronary collateral circulation, thereby increasing coronary blood flow.

Lomeza is a broad-spectrum quinolone antibiotic that has bactericidal effects on Gram-negative bacteria, Gram-positive bacteria and some anaerobic bacteria. It has good antibacterial effects on methicillin-resistant Staphylococcus aureus, ampicillin-resistant influenza bacilli, pipemidic acid-resistant Escherichia coli and bacteria resistant to other drugs. Its antibacterial mechanism is to inhibit the activity of bacterial DNA helicase, thereby inhibiting bacterial DNA transcription and replication, and has bactericidal effects on a variety of Gram-positive and Gram-negative bacteria.

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and inhibit bacterial DNA replication. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, influenza bacillus, some Escherichia coli, Pseudomonas aeruginosa, and gonococci; it also has good antibacterial effect against some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc.

Quinolone antibacterial drugs inhibit bacterial DNA helicase and have a broad-spectrum antibacterial effect. They have strong antibacterial activity against Enterobacter bacteria such as Escherichia coli, Klebsiella, Proteus, Shigella, Salmonella typhi, etc., as well as influenza bacillus and Neisseria. They also have certain antibacterial effects on Staphylococcus aureus and Pseudomonas aeruginosa. They have only mild effects on pneumococci, various groups of streptococci and enterococci.

Pefloxacin mesylate is a quinolone antibacterial drug, and its mechanism of action is to inhibit bacterial DNA helicase. It has a broad-spectrum antibacterial effect, and has strong antibacterial activity against Enterobacter bacteria such as Escherichia coli, Klebsiella, Proteus, Shigella, Salmonella typhi, etc., as well as influenza bacillus, Neisseria, etc. It also has a certain antibacterial effect on Staphylococcus aureus and Pseudomonas aeruginosa. It has only a mild effect on pneumococci, various groups of streptococci and enterococci.